Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 7/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9137891 | 0.94 | PAOX (0.46) | KDM4EMAPK1HIF1APAOXPLA2G4A | |
| SCHEMBL17297122 | 0.92 | PAOX (0.48) | KDM4EMAPK1HIF1APAOXPLA2G4A | |
| SCHEMBL10301546 | 0.92 | PAOX (0.48) | KDM4EMAPK1HIF1APAOXPLA2G4A | |
| SCHEMBL15535068 | 0.86 | ALDH1A1 (0.41) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL19658369 | 0.86 | KDM4E (0.46) | KDM4EMAPK1HIF1APAOXPLA2G4A | |
| SCHEMBL632876 | 0.86 | KDM4E (0.46) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL907569 | 0.86 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXALDH1A1 | |
| SCHEMBL1557480 | 0.85 | ADRA1A (0.53) | MAPK1PLA2G4AADRA1APLA2G2A | |
| SCHEMBL7113895 | 0.85 | TDP1 (0.39) | KDM4EMAPK1HIF1APAOXPLA2G4A | |
| SCHEMBL8775294 | 0.84 | KDM4E (0.56) | KDM4EMAPK1HIF1APAOXALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | KDM4E 1948/4885MAPK1 2582/4885HIF1A 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.